Item 8.01. Other Events.

On November 5, 2012, Ventrus Biosciences, Inc. issued a press release announcing that it had received written feedback from the U.S. Food and Drug Administration regarding its planned new drug application, or NDA, for diltiazem hydrochloride cream (VEN 307) in anal fissures and that, following completion of the recently begun Phase 3 clinical trial, it expects to file the NDA late in the fourth quarter of 2013. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Attached hereto as Exhibit 99.2, and incorporated herein by reference, is a PowerPoint presentation that Ventrus will present on its call scheduled for 10:00 a.m., Monday, November 5, to discuss VEN 307.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits Exhibit No. Description 99.1 Press release dated November 5, 2012. 99.2 PowerPoint presentation of November 5, 2012.